Suvizumab  (Synonyms: 舒维组单抗; KD-247)

Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1_MN, HIV-1_SF2 and HIV-1_89.6 with IC₅₀ values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Suvizumab 对 G314E 突变的假型病毒表现出高度抗性^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Suvizumab (15、30 和 45 mg/kg；静脉注射；单剂量) 在感染 SHIV C2/1 的食蟹猴中，以剂量依赖性方式弱化了病毒攻击和血浆病毒血症，增加了 CD4⁺ T 细胞数^[2]。
Suvizumab (45 mg/kg；静脉注射；一周一次持续 2 个月) 在感染猿猴/人类免疫缺陷病毒-C2/1 的雄性食蟹猴中，降低了淋巴组织中 CD4 T 细胞的损失^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

914257-21-9

液体

Colorless to light yellow

舒维组单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62.  [Content Brief]

  [2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70.  [Content Brief]

  [3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73.  [Content Brief]

  [4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94.  [Content Brief]